Cytek Biosciences Inc (CTKB) — Capital Reinvestment Ratio
Cytek Biosciences Inc (CTKB) has a Capital Reinvestment Ratio of 14.60x as of June 2025, meaning it reinvests 15% of its operating cash flow ($108.00K) in capital expenditures ($1.58 Million). Check tangible net worth ratio of Cytek Biosciences Inc to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Cytek Biosciences Inc Capital Reinvestment Ratio (2020–2024)
This chart tracks Cytek Biosciences Inc's Capital Reinvestment Ratio across 4 annual periods. For the full cash flow conversion analysis, see CTKB operating cash flow.
Annual Capital Reinvestment Ratio for Cytek Biosciences Inc (2020–2024)
Year-by-year Capital Reinvestment Ratio for Cytek Biosciences Inc from 2020 to 2024. See cash generation quality of Cytek Biosciences Inc to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.14x | $25.38 Million | $3.52 Million | ▼ -84.8% |
| 2023 | 0.91x | $5.28 Million | $4.83 Million | ▼ -3.0% |
| 2021 | 0.94x | $4.63 Million | $4.36 Million | ▲ +823.4% |
| 2020 | 0.10x | $15.16 Million | $1.55 Million | — |